Meeting
2021 Genitourinary Cancers Symposium
Racial disparities in efficacy of first-line abiraterone in metastatic castrate-resistant prostate cancer (mCRPC).
Authors
Mallika Marar
University of Pennsylvania, Philadelphia, PA
Mallika Marar , Qi Long , Ronac Mamtani , Vivek Narayan , Neha Vapiwala , Ravi Bharat Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Cancer Disparities
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 20)
DOI
10.1200/JCO.2021.39.6_suppl.20
Abstract #
20
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1).
First Author: Antonin Broyelle
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2017 Genitourinary Cancers Symposium
Abiraterone acetate with prednisone and cabazitaxel as subsequent treatment after first-line docetaxel in metastatic castrate-resistant prostate cancer (mCRPC): Final efficacy and safety analysis of the CAPRO study.
First Author: Arancha Gonzalez del Alba
Poster
2014 Genitourinary Cancers Symposium
The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: Experience from seven U.K. centers.
First Author: Robert Stevenson